Skip to main content
. 2020 May 25;9(2):473–482. doi: 10.1007/s40120-020-00194-4

Fig. 2.

Fig. 2

Number (%) of patients with comorbidities of interest during the 1-year follow-up. Of the potentially ATTRv-related comorbidities, neuropathy affected the most patients [n (%) = 56 (30.3%)] and vitreous opacity the least [5 (2.7%)]